Description
Ninlaro (Ixazomib) 2.3mg Online
Ninlaro (Ixazomib) is a medicine that targets proteins in cancer cells and stops the cancer cells from growing. It is used to treat multiple myeloma. Ninlaro is used in combination with chemotherapy to treat multiple myeloma (bone marrow cancer). Ninlaro is given together with lenalidomide and a steroid medicine called dexamethasone. Ninlaro is usually given after at least one other cancer medicine has been tried without success.
Ninlaro a second-generation proteasome inhibitor (PI) and the first oral PI approved by the FDA in November 2015 for multiple myeloma treatment in combination with 2 other therapies (lenalidomide and dexamethasone) for patients who have received at least 1 prior therapy. It was found to have similar efficacy to bortezomib (the first PI approved for multiple myeloma therapy) in the control of myeloma growth and prevention of bone loss. Ninlaro citrate is marketed by Takeda Pharmaceuticals under the brand name Ninlaro, which is a prodrug that becomes quickly converted to its active metabolite, Ninlaro, after administration.
Ninlaro should be taken once a week on the same day and at approximately the same time for the first three weeks of a four-week cycle. Ninlaro should be taken at least one hour before or at least two hours after food. The whole capsule should be swallowed with water. The capsule should not be crushed, chewed, or opened.
